Performance of plasma Aβ42/Aβ40 ratio, measured with a novel HPLC-MS/MS method, as a biomarker of amyloid-PET status in a DPUK-KOREAN cohort
<p><strong>Background:</strong> We assessed the feasibility of plasma Aβ42/Aβ40 determined using a novel liquid chromatography-mass spectrometry method (LC-MS) as a useful biomarker of PET status in a Korean cohort from the DPUK Study.</p> <p><strong>Methods:<...
| Main Authors: | , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
BioMed Central
2021
|
| _version_ | 1797066022882115584 |
|---|---|
| author | Jang, H Kim, C-H Seo, SW Na, D Gallagher, J Seo, SW |
| author_facet | Jang, H Kim, C-H Seo, SW Na, D Gallagher, J Seo, SW |
| author_sort | Jang, H |
| collection | OXFORD |
| description | <p><strong>Background:</strong> We assessed the feasibility of plasma Aβ42/Aβ40 determined using a novel liquid chromatography-mass spectrometry method (LC-MS) as a useful biomarker of PET status in a Korean cohort from the DPUK Study.</p>
<p><strong>Methods:</strong> A total of 580 participants belonging to six groups, Alzheimer´s disease dementia (ADD, n=134), amnestic mild cognitive impairment (aMCI, n=212), old controls (OC, n=149), young controls (YC, n=15), subcortical vascular cognitive impairment (SVCI, n=58), and cerebral amyloid angiopathy (CAA, n=12), were included in this study. Plasma Aβ40 and Aβ42 were quantitated using a new antibody-free, HPLC-MS/MS, which drastically reduced the sample preparation time and cost. We performed receiver operating characteristic (ROC) analysis to develop the cutoff of Aβ42/Aβ40 and investigated its performance predicting centiloid (CL)-based PET positivity (PET+).</p>
<p><strong>Results:</strong> Aβ42/Aβ40 ratios were lower for PET positive individuals in the ADD, aMCI, OC, and SVCI (p<0.001) groups, but not in CAA group (p=0.133). In the group of YC, OC, aMCI and ADD groups, plasma Aβ42/Aβ40 predicted PET+ with an area under the ROC curve (AUC) of 0.814 at a cutoff of 0.2576. When adding age, APOE4, and diagnosis, the AUC significantly improved to 0.912.</p>
<p><strong>Conclusion:</strong> Plasma Aβ42/Aβ40 ratio, as measured by this novel LC-MS method, showed good discriminating performance based on PET positivity.</p> |
| first_indexed | 2024-03-06T21:36:30Z |
| format | Journal article |
| id | oxford-uuid:46725f62-14ea-4dfe-94c6-eddfdd6d91ee |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-06T21:36:30Z |
| publishDate | 2021 |
| publisher | BioMed Central |
| record_format | dspace |
| spelling | oxford-uuid:46725f62-14ea-4dfe-94c6-eddfdd6d91ee2022-03-26T15:13:46ZPerformance of plasma Aβ42/Aβ40 ratio, measured with a novel HPLC-MS/MS method, as a biomarker of amyloid-PET status in a DPUK-KOREAN cohortJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:46725f62-14ea-4dfe-94c6-eddfdd6d91eeEnglishSymplectic ElementsBioMed Central2021Jang, HKim, C-HSeo, SWNa, DGallagher, JSeo, SW<p><strong>Background:</strong> We assessed the feasibility of plasma Aβ42/Aβ40 determined using a novel liquid chromatography-mass spectrometry method (LC-MS) as a useful biomarker of PET status in a Korean cohort from the DPUK Study.</p> <p><strong>Methods:</strong> A total of 580 participants belonging to six groups, Alzheimer´s disease dementia (ADD, n=134), amnestic mild cognitive impairment (aMCI, n=212), old controls (OC, n=149), young controls (YC, n=15), subcortical vascular cognitive impairment (SVCI, n=58), and cerebral amyloid angiopathy (CAA, n=12), were included in this study. Plasma Aβ40 and Aβ42 were quantitated using a new antibody-free, HPLC-MS/MS, which drastically reduced the sample preparation time and cost. We performed receiver operating characteristic (ROC) analysis to develop the cutoff of Aβ42/Aβ40 and investigated its performance predicting centiloid (CL)-based PET positivity (PET+).</p> <p><strong>Results:</strong> Aβ42/Aβ40 ratios were lower for PET positive individuals in the ADD, aMCI, OC, and SVCI (p<0.001) groups, but not in CAA group (p=0.133). In the group of YC, OC, aMCI and ADD groups, plasma Aβ42/Aβ40 predicted PET+ with an area under the ROC curve (AUC) of 0.814 at a cutoff of 0.2576. When adding age, APOE4, and diagnosis, the AUC significantly improved to 0.912.</p> <p><strong>Conclusion:</strong> Plasma Aβ42/Aβ40 ratio, as measured by this novel LC-MS method, showed good discriminating performance based on PET positivity.</p> |
| spellingShingle | Jang, H Kim, C-H Seo, SW Na, D Gallagher, J Seo, SW Performance of plasma Aβ42/Aβ40 ratio, measured with a novel HPLC-MS/MS method, as a biomarker of amyloid-PET status in a DPUK-KOREAN cohort |
| title | Performance of plasma Aβ42/Aβ40 ratio, measured with a novel HPLC-MS/MS method, as a biomarker of amyloid-PET status in a DPUK-KOREAN cohort |
| title_full | Performance of plasma Aβ42/Aβ40 ratio, measured with a novel HPLC-MS/MS method, as a biomarker of amyloid-PET status in a DPUK-KOREAN cohort |
| title_fullStr | Performance of plasma Aβ42/Aβ40 ratio, measured with a novel HPLC-MS/MS method, as a biomarker of amyloid-PET status in a DPUK-KOREAN cohort |
| title_full_unstemmed | Performance of plasma Aβ42/Aβ40 ratio, measured with a novel HPLC-MS/MS method, as a biomarker of amyloid-PET status in a DPUK-KOREAN cohort |
| title_short | Performance of plasma Aβ42/Aβ40 ratio, measured with a novel HPLC-MS/MS method, as a biomarker of amyloid-PET status in a DPUK-KOREAN cohort |
| title_sort | performance of plasma aβ42 aβ40 ratio measured with a novel hplc ms ms method as a biomarker of amyloid pet status in a dpuk korean cohort |
| work_keys_str_mv | AT jangh performanceofplasmaab42ab40ratiomeasuredwithanovelhplcmsmsmethodasabiomarkerofamyloidpetstatusinadpukkoreancohort AT kimch performanceofplasmaab42ab40ratiomeasuredwithanovelhplcmsmsmethodasabiomarkerofamyloidpetstatusinadpukkoreancohort AT seosw performanceofplasmaab42ab40ratiomeasuredwithanovelhplcmsmsmethodasabiomarkerofamyloidpetstatusinadpukkoreancohort AT nad performanceofplasmaab42ab40ratiomeasuredwithanovelhplcmsmsmethodasabiomarkerofamyloidpetstatusinadpukkoreancohort AT gallagherj performanceofplasmaab42ab40ratiomeasuredwithanovelhplcmsmsmethodasabiomarkerofamyloidpetstatusinadpukkoreancohort AT seosw performanceofplasmaab42ab40ratiomeasuredwithanovelhplcmsmsmethodasabiomarkerofamyloidpetstatusinadpukkoreancohort |